Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc.

Arrivent is a company that specializes in providing innovative solutions in the technology sector. The company focuses on leveraging cutting-edge technology to deliver products and services that enhance efficiency and drive digital transformation for its clients.

Bing Yao

Stuart Lutzker

Arrivent

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Shaun Foy

Rodger Novak

Daniel Anderson

Emmanuelle Charpentier

CRISPR Therapeutics AG

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Feng Zhang

David R. Liu

George Church

J. Keith Joung

Jennifer Doudna

Editas Medicine, Inc.

Instil Bio is involved in the development of novel cell therapies for cancer treatment. The company focuses on advancing its clinical pipelines.

Metric
Company Name	Instil Bio, Inc.	Arrivent	CRISPR Therapeutics AG	Editas Medicine, Inc.
Symbol	TIL		CRSP	EDIT
MSH ID	COM:INSTILBIO	COM:ARRIVENT	COM:CRISPRTX	COM:EDITASMEDICINE
Market	STOCKS	PRIVATE	STOCKS	STOCKS
Sector	Healthcare	Technology	Healthcare	Healthcare
Industry	Biotechnology	Technology Solutions	Biotechnology	Biotechnology
Country	US		CH	US
Stage
Employee Count	49	44	407	265
Website	instilbio.com	arrivent.com	crisprtx.com	editasmedicine.com
LinkedIn		arrivent	crispr-therapeutics
Founders

Metric
Market Cap	65.10M	4.72B	417.77M
Enterprise Value
Monthly Web Traffic	12.72K		38.30K
Web Traffic Growth	-0.76		2.72
Valuation
Raised Capital			125M

Metric
Revenue	370M	78.12M
Revenue (LTM)
Revenue (NTM)
Gross Profit	239.75M	72.06M
EBITDA	-202.70M	-163.12M
Operating Income	-222.54M	-169.18M
Net Income	-153.61M	-153.22M
EPS	-1.94	-2.02
Diluted EPS	-1.94	-2.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.65	0.93
Operating Profit Margin	-0.60	-2.10
EBITDA Margin	-0.55	-2.09
Net Profit Margin	-0.42	-1.92
Return on Equity	-0.08	-0.42
Return on Assets	-0.07	-0.30
Return on Capital Employed	-0.10	-0.38

COM:INSTILBIO

Instil Bio

Last Close

24.76

22/11 21:00

Market Cap

65.10M

Beta: -

Volume Today

91.17K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-14.48	-3.11
P/B Ratio	2.96	1.60
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	21.12	7.93
EV Multiple	-11.92	-1.33

Metric
Days Sales Outstanding		35.92
Days Payables Outstanding	81.53
Days Inventory Outstanding		0.00
Operating Cycle	197.30	47.59
Cash Conversion Cycle	90.40	-450.13
Asset Turnover	0.17	0.17

Metric
Operating Cash Flow	-260.38M	-132.18M
Free Cash Flow	-272.35M	-136.90M
Cash Flow to Debt	-0.11	-3.62
Operating Cash Flow/Sales	-0.13	-1.69
Free Cash Flow Yield	-0.06	-0.20

Metric
Cash & Equivalents	389.48M	123.65M
Accounts Receivable	-200M	-5.04M
Inventory
Goodwill
Debt to Capitalization	0.11	0.14
Debt to Assets	0.12	0.07
Current Ratio	15.83	7.62
Quick Ratio	17.81	5.27

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.50	0.74
R&D to Revenue	2.33	5.08
SG&A to Revenue	0.48	2.97